Submissions for variant NM_000059.4(BRCA2):c.5692del (p.Asp1898fs)

dbSNP: rs398122539

Total submissions: 11

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000076940	SCV000300917	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2016-09-08	reviewed by expert panel	curation	Variant allele predicted to encode a truncated non-functional protein.
GeneDx	RCV000235464	SCV000293479	pathogenic	not provided	2023-07-27	criteria provided, single submitter	clinical testing	Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Observed in at least two individuals with a personal or family history of breast and/or ovarian cancer (Dworkin et al., 2009; Churpek et al., 2015); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 5920delG; This variant is associated with the following publications: (PMID: 19340607, 25428789)
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge	RCV000076940	SCV000327265	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2015-10-02	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV000461953	SCV000549724	pathogenic	Hereditary breast ovarian cancer syndrome	2022-09-27	criteria provided, single submitter	clinical testing	This variant is also known as 5920delG. ClinVar contains an entry for this variant (Variation ID: 91423). For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 19340607, 25428789). This sequence change creates a premature translational stop signal (p.Asp1898Metfs*11) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000461953	SCV000694892	pathogenic	Hereditary breast ovarian cancer syndrome	2022-09-27	criteria provided, single submitter	clinical testing	Variant summary: BRCA2 c.5692delG (p.Asp1898MetfsX11) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory and associated with HBOC phenotype in HGMD. The variant was absent in 250668 control chromosomes. c.5692delG has been reported in the literature in individuals affected with clinically diagnosed Breast Cancer (Churpek_2015 and Dworkin_2009). These data indicate that the variant is likely associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics	RCV001024414	SCV001186428	pathogenic	Hereditary cancer-predisposing syndrome	2024-04-26	criteria provided, single submitter	clinical testing	The c.5692delG pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of one nucleotide at nucleotide position 5692, causing a translational frameshift with a predicted alternate stop codon (p.D1898Mfs*11). This mutation, also designated as 5920delG, has previously been detected in multiple breast cancer patients (Churpek JE et al. Breast Cancer Res. Treat. 2015 Jan;149:31-9; Dworkin AM et al. Fam. Cancer. 2009 Apr;8:339-46). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Color Diagnostics, LLC DBA Color Health	RCV001024414	SCV001353296	pathogenic	Hereditary cancer-predisposing syndrome	2020-01-15	criteria provided, single submitter	clinical testing	This variant deletes 1 nucleotide in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Baylor Genetics	RCV003460720	SCV004216162	pathogenic	Familial cancer of breast	2023-05-04	criteria provided, single submitter	clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000235464	SCV004219697	pathogenic	not provided	2022-10-11	criteria provided, single submitter	clinical testing	This frameshift variant alters the translational reading frame of the BRCA2 mRNA and causes the premature termination of BRCA2 protein synthesis. It has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, the variant has been reported in an individual with breast cancer (PMID: 25428789 (2015)). It has also been reported in a world-wide screening study of families with BRCA1 and BRCA2 pathogenic variants (PMID: 29446198 (2018)). Based on the available information, this variant is classified as pathogenic.
Sharing Clinical Reports Project (SCRP)	RCV000076940	SCV000108737	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2010-09-08	no assertion criteria provided	clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto	RCV000461953	SCV000587793	pathogenic	Hereditary breast ovarian cancer syndrome	2014-01-31	no assertion criteria provided	research